Cite
MLA Citation
David Schaer et al.. “Targeting the TGFβ pathway with galunisertib, a TGFβRI SMI, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint inhibition.” Journal for immunotherapy of cancer, vol. 3, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100135566260.0x000007